Caio Suartz

Just published in European Urology Oncology, our paper on ctDNA in bladder cancer. A noninvasive biomarker that could nos ajudar to reflects tumor burden, predicts treatment response, and identifies recurrence earlier than standard methods. Take a look 🧵

@MarcMachaalani @YaleIMed @DrChoueiri @BraunMDPhD @VincentWenxinXu @Clara__Steiner @eddy_saad @yekeduz_emre @ReneeSaliby @AminNassarMD @thenasheffect @TalalZarif1 Congratulations 👏🏼

Thrilled to have matched at @YaleIMed! Beyond grateful to my amazing mentors, friends, and family for supporting me every step of the way! #Match2026

@NOSMUUrology @thenosm @waleedshabana @ShahrourWalid Excellent ! 👏🏼 Happy to have you on the team

Welcome aboard @thenosm @waleedshabana @ShahrourWalid @CSuartz

High-level science. Meaningful dialogue. Real impact for our patients. #ASCOGU #UroOncology #BladderCancer #ProstateCancer

14th Canadian Night at ASCO GU 🇨🇦 An inspiring evening highlighting the strength of global collaboration in uro-oncology. Honored to learn from world leaders such as Andrea Necchi and Fred Saad, discussing emerging paradigms and the future of genitourinary cancer care.

Very elegant and thoughtful discussion by @DrTylerStewart #ASCOGU2026 1. B-15: EV-P as the new SOC in MIBC, highlights Qs re: no. of cycles & future of bladder preservation 2. RC48G001: 2nd line DV in mUC- future role of DV in the fifteen landscape? @tompowles1 @MattGalsky @Uromigos @OncoAlert @DrChoueiri @ERPlimackMD @apolo_andrea @brian_rini

@NOSMUUrology @ShahrourWalid

Honored to present two posters at ASCO GU 2026 and to represent the Northern Ontario School of Medicine and Thunder Bay Regional Health Sciences Centre. ASCO GU is one of the most important global meetings in genitourinary oncology — where practice-changing trials are presented.

New IBCG consensus: Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group (IBCG) Full text: authors.elsevier.com/a/1mf5C_6tuO0S… @shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery

Original Article: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (phase 3 KEYNOTE-905/EV-303 trial) nej.md/4czl8sG Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T #Oncology

In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: nej.md/4czl8sG Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T

PGY-2’s first time at the console, learning a key step of robotic radical prostatectomy: bladder drop. Stepwise training, safety first, real learning. Extremely rewarding to watch this growth in real time. @NOSMUUrology @ShahrourWalid

It is a tremendous honor to take part in the largest urology congress and to deliver a lecture on topics that truly motivate me: robotic surgery and artificial intelligence. It will be an extraordinary experience. I am already looking forward to AUA 2026. Many thanks to AUA 2026

Very happy to have 3 abstracts accepted at AUA 2026. Washington, DC — here we come!

Closing 2025 with 17 publications in journals with impact factor >2. Grateful to all collaborators for this collective achievement an honored to be invited by the AUA to deliver a 2026 lecture on «robotic surgery — Outcomes-based and evidence-focused perspective». Truly grateful.

@Wisdom_HQ Our attempt failed

JUST IN: EVP does it again! Positive EV-304 data (following @myESMO 2025 with EV-303 trial): EVP improves EFS and OS in in cisplatin-ELIGIBLE patients with muscle-invasive bladder cancer! pfizer.com/news/press-rel…

Journal Club – Excellent presentations by our residents: Hussein (PGY-1), presenting the OPTIMUS trial, and Denis (PGY-2), presenting radiotherapy to prostate cancer w 80 Gy plus ADT from the GETUG trial.